Product Comparison

Comparison Options

• Print
• Email
• Export Compare

McKesson #	1212568	1194022	1194021	1212567	1221601
Description	SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection 2.4 mL	SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection 1 mL	SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection 1 mL	SKYRIZI® Risankizumab-rzaa 60 mg / mL Injection 10 mL	SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection 1.2 mL
Manufacturer #	00074107001	00074210001	00074105001	00074501501	0074106501
Brand	SKYRIZI®	SKYRIZI®	SKYRIZI®	SKYRIZI®	SKYRIZI®
Manufacturer	AbbVie US LLC	AbbVie Inc	AbbVie Inc	AbbVie US LLC	AbbVie US LLC
Invoice	SKYRIZI, INJ 360MG/2.4ML PF CARTRIDGE W/OBI D/S	SKYRIZI, PEN 150MG/ML	SKYRIZI, PFS 150MG/ML	SKYRIZI, SDV 600MG/10ML D/S	SKYRIZI, INJ 180MG/1.2ML PF CARTRIDGE W/OBI D/S
	Log In to Order	Log In to Order	Log In to Order	Log In to Order	Log In to Order
Comparison
Container Type	Single-Dose Prefilled Cartridge	Prefilled Auto-Injector	Prefilled Syringe	Single-Dose Vial	Single-Dose Prefilled Cartridge
Generic Drug Code	52475	49591	49617	52473	53397
NDC Number	00074107001	00074210001	00074105001	00074501501	00074106501
Strength	150 mg / mL	150 mg / mL	150 mg / mL	60 mg / mL	150 mg / mL
Type	Subcutaneous	Subcutaneous	Subcutaneous	Intravenous	Subcutaneous
UNSPSC Code	42142619	51241200	51241200	42142619	51241200
Volume	2.4 mL	1 mL	1 mL	10 mL	1.2 mL
Application	Monoclonal Antibody	Monoclonal Antibody	Monoclonal Antibody	Monoclonal Antibody	Monoclonal Antibody
Country of Origin	Unknown	Unknown	Unknown	Unknown	Unknown
Dosage Form	Injection	Injection	Injection	Injection	Injection
Generic Drug Name	Risankizumab-rzaa	Risankizumab-rzaa	Risankizumab-rzaa	Risankizumab-rzaa	Risankizumab-rzaa
Product Dating	McKesson Acceptable Dating: we will ship >= 180 days	McKesson Acceptable Dating: we will ship >= 180 days	McKesson Acceptable Dating: we will ship >= 180 days	McKesson Acceptable Dating: we will ship >= 180 days	McKesson Acceptable Dating: we will ship >= 180 days
Storage Requirements	Requires Refrigeration	Requires Refrigeration	Requires Refrigeration	Requires Refrigeration	Requires Refrigeration
Features and Benefits	SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults 360 mg/2.4 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector Store in a refrigerator at 36°F to 46° F (2°C to 8°C)	SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy Single-Dose Pen	SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy Single-Dose Prefilled Syringe	SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults 600 mg/10 mL (60 mg/mL) single-dose vial	SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy 180 mg/1.2 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector